The FDA expanded Travere Therapeutics’ Filspari label to include focal segmental glomerulosclerosis (FSGS), making it the first approved therapy in the US for the kidney disease. The update follows the drug’s prior use for other indications, extending its reach to an additional glomerular disorder. Clinicians will now have an FDA-approved oral option specifically for FSGS patients, a population with limited labeled treatments and significant unmet need. The label change indicates sufficient evidence for safety and efficacy in this setting. For biopharma companies tracking kidney-care regulatory outcomes, the decision highlights continued agency willingness to expand label scope within established product programs. It also underscores ongoing demand for therapies that can be taken as pills rather than infusions or complex regimens. Filspari’s new status as “first therapy” may influence prescribing patterns and payer coverage decisions for FSGS as formularies update.